<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The VELOUR and VITAL studies recently demonstrated ziv-aflibercept improved overall survival in patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC), including those previously treated with bevacizumab, but did not improve overall survival in <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, VEGF-directed agents might be useful throughout the continuum of care in mCRC, but biomarkers are needed to identify patients likely to benefit </plain></SENT>
</text></document>